WCM Investment Management LLC Purchases 17,125 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

WCM Investment Management LLC raised its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 30.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 72,860 shares of the company's stock after buying an additional 17,125 shares during the period. WCM Investment Management LLC owned about 0.24% of Inspire Medical Systems worth $11,457,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Inspire Medical Systems by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 3,270,357 shares of the company's stock worth $606,259,000 after buying an additional 38,219 shares during the period. Dragoneer Investment Group LLC bought a new stake in Inspire Medical Systems during the fourth quarter valued at $161,486,000. Invesco Ltd. grew its holdings in Inspire Medical Systems by 14.3% during the 4th quarter. Invesco Ltd. now owns 793,080 shares of the company's stock worth $147,021,000 after acquiring an additional 99,030 shares during the period. Janus Henderson Group PLC raised its position in shares of Inspire Medical Systems by 12.9% in the 4th quarter. Janus Henderson Group PLC now owns 567,312 shares of the company's stock worth $105,173,000 after acquiring an additional 64,703 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Inspire Medical Systems by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 486,341 shares of the company's stock worth $90,188,000 after acquiring an additional 2,687 shares in the last quarter. Institutional investors own 94.91% of the company's stock.

Insiders Place Their Bets

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $160.00, for a total transaction of $57,600.00. Following the completion of the sale, the director directly owned 24,046 shares of the company's stock, valued at approximately $3,847,360. The trade was a 1.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.10% of the company's stock.

Inspire Medical Systems Trading Down 1.8%

Shares of INSP traded down $2.34 during trading hours on Thursday, reaching $128.39. The stock had a trading volume of 301,417 shares, compared to its average volume of 550,541. The firm has a 50-day simple moving average of $142.87 and a 200 day simple moving average of $164.35. Inspire Medical Systems, Inc. has a 12 month low of $123.00 and a 12 month high of $225.00. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of 59.16, a P/E/G ratio of 2.00 and a beta of 1.25.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.33. The firm had revenue of $201.32 million for the quarter, compared to the consensus estimate of $194.89 million. Inspire Medical Systems had a net margin of 7.92% and a return on equity of 10.00%. The business's revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.34) earnings per share. On average, equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Analysts Set New Price Targets

INSP has been the topic of several research analyst reports. Stifel Nicolaus cut their target price on Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Wells Fargo & Company cut their price target on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. KeyCorp lowered their price objective on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research note on Monday, April 21st. Finally, Robert W. Baird boosted their target price on shares of Inspire Medical Systems from $230.00 to $236.00 and gave the company an "outperform" rating in a research report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $211.91.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.